STRO logo

SUTRO BIOPHARMA INC

STRONASDAQ
πŸ† #3687 by market capEarnings Mar 22US Equity
$8.60β–Ό $0.12 (βˆ’1.38%)
Market closed Β· at close
πŸ””
Track STRO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.4%
7dβ–Ό 12.5%
14dβ–Ό 10.7%
30dβ–Ό 7.8%
ytdβ–Ό 25.0%
1yβ–² 1.6%
🏦Market Cap
$143M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-56.3%
Declining
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
47.3%
Strong
βš–οΈP/S Ratio
3.1x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$8.46 – $8.99
52-Week Range
$7.15 – $43.85
Volume (shares)
275,898
Avg Volume (shares)
β€”
Shares Outstanding
16.6M
Next Earnings
2027-03-22

Fundamentals Snapshot

Annual Revenue
$102M
Last Q Revenue
$9M
P/E Ratio
β€”
P/S Ratio
3.1x
EPS (TTM)
$-17.32
Dividend Yield
β€”
Dilution (1yr)
+4.0%
STRO logo

SUTRO BIOPHARMA INC

STRO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$102Mβ–² +65.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
92.9%β–² +5.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$105Mβ–Ό βˆ’56.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$179Mβ–Ό βˆ’8.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.6Mβ–² +4.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$177Mβ–Ό βˆ’$344M YoY
StockOtter Β· stockotter.space

About SUTRO BIOPHARMA INC

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·10d ago

Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –

Zacks Investment ResearchΒ·18d ago

Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks

The heavy selling pressure might have exhausted for Sutro Biopharma (STRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising ea

GlobeNewsWireΒ·18d ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO),Β a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjug

Zacks Investment ResearchΒ·19d ago

Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround

Sutro Biopharma (STRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings esti

GlobeNewsWireΒ·Oct 21

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

β€” STRO-006 is Sutro's second wholly-owned ADC to enter the clinic in less than one year β€” Β Β Β Β Β Β β€” Initial clinical data expected in the second half of 2027 β€” SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) --

GlobeNewsWireΒ·Sep 29

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conju